PMV Pharma Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 54

Employees

  • Stock Symbol
  • PMVP

Stock Symbol

  • Share Price
  • $1.31
  • (As of Thursday Closing)

PMV Pharma General Information

Description

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Contact Information

Formerly Known As
PJ Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 400 Alexander Park Drive
  • Suite 301
  • Princeton, NJ 08540
  • United States
+1 (609)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 400 Alexander Park Drive
  • Suite 301
  • Princeton, NJ 08540
  • United States
+1 (609)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PMV Pharma Stock Performance

As of 19-Nov-2026, PMV Pharma’s stock price is $1.31. Its current market cap is $99M with 75.5M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.31 $1.22 $1.02 - $1.91 $99M 75.5M 715K -$1.56

PMV Pharma Financials Summary

As of 30-Sep-2026, PMV Pharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 46,893 (61,805) (91,436) (30,630)
Revenue 0 0 0 0
EBITDA (92,227) (86,118) (84,320) (78,872)
Net Income (88,533) (77,742) (58,709) (68,960)
Total Assets 111,404 116,562 191,288 252,152
Total Debt 138 838 1,190 13,286
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PMV Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PMV Pharma‘s full profile, request access.

Request a free trial

PMV Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore PMV Pharma‘s full profile, request access.

Request a free trial

PMV Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small
Drug Discovery
Princeton, NJ
54 As of 2026

Iselin, NJ
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PMV Pharma Competitors (57)

One of PMV Pharma’s 57 competitors is Outlook Therapeutics, a Formerly VC-backed company based in Iselin, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Outlook Therapeutics Formerly VC-backed Iselin, NJ
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Valerio Therapeutics Formerly VC-backed Paris, France
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 57 competitors. Get the full list »

PMV Pharma Patents

PMV Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026228825-A1 Crystalline forms of plk4 modulating compounds Pending 30-Apr-2025
AU-2024369826-A1 Plk4 modulators Pending 30-Oct-2023
EP-4801907-A1 Plk4 modulators Pending 30-Oct-2023
WO-2025096463-A1 Plk4 modulators Inactive 30-Oct-2023
AU-2024359526-A1 Methods of treating conditions with mutant p53 reactivating compounds Pending 10-Oct-2023 A61P35/00
To view PMV Pharma’s complete patent history, request access »

PMV Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PMV Pharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.27 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view PMV Pharma’s complete esg history, request access »

PMV Pharma FAQs

  • When was PMV Pharma founded?

    PMV Pharma was founded in 2013.

  • Where is PMV Pharma headquartered?

    PMV Pharma is headquartered in Princeton, NJ.

  • What is the size of PMV Pharma?

    PMV Pharma has 54 total employees.

  • What industry is PMV Pharma in?

    PMV Pharma’s primary industry is Drug Discovery.

  • Is PMV Pharma a private or public company?

    PMV Pharma is a Public company.

  • What is PMV Pharma’s stock symbol?

    The ticker symbol for PMV Pharma is PMVP.

  • What is the current stock price of PMV Pharma?

    As of 19-Nov-2026 the stock price of PMV Pharma is $1.31.

  • What is the current market cap of PMV Pharma?

    The current market capitalization of PMV Pharma is $99M.

  • Who are PMV Pharma’s competitors?

    Outlook Therapeutics, Marengo Therapeutics, Valerio Therapeutics, CytomX Therapeutics, and Xenetic Biosciences are some of the 57 competitors of PMV Pharma.

  • What is PMV Pharma’s annual earnings per share (EPS)?

    PMV Pharma’s EPS for 12 months was -$1.56.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process